Literature DB >> 24519662

[Upstream therapy for atrial fibrillation].

Andreas Goette1, Matthias Hammwöhner, Alicja Bukowska.   

Abstract

In recent years a tremendous amount has been learned about the pathophysiology of atrial fibrillation (AF) which induces electrophysiological changes in the right and left atrium. Besides calcium-dependent tissue changes which are induced by activation of proteases and phosphatases, such as calpain and calcineurin, concomitant cardiac diseases activate the atrial angiotensin II system. Experiments have shown positive effects of statins in AF models. In contrast, clinical studies have provided heterogeneous results. Of note, several studies have shown that therapy with angiotensin II receptor blockers or statins does not influence the recurrence of AF.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24519662     DOI: 10.1007/s00399-014-0303-0

Source DB:  PubMed          Journal:  Herzschrittmacherther Elektrophysiol        ISSN: 0938-7412


  42 in total

Review 1.  Electrophysiological effects of angiotensin II. Part I: signal transduction and basic electrophysiological mechanisms.

Authors:  Andreas Goette; Uwe Lendeckel
Journal:  Europace       Date:  2008-02       Impact factor: 5.214

2.  Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence.

Authors:  Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang
Journal:  Circulation       Date:  2006-07-03       Impact factor: 29.690

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

Review 4.  MicroRNAs and atrial fibrillation: new fundamentals.

Authors:  Zhiguo Wang; Yanjie Lu; Baofeng Yang
Journal:  Cardiovasc Res       Date:  2010-11-04       Impact factor: 10.787

5.  Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation.

Authors:  A Goette; T Staack; C Röcken; M Arndt; J C Geller; C Huth; S Ansorge; H U Klein; U Lendeckel
Journal:  J Am Coll Cardiol       Date:  2000-05       Impact factor: 24.094

6.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Authors:  Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

Review 7.  [Current antiarrhythmic drug therapy in atrial fibrillation].

Authors:  A Goette
Journal:  Dtsch Med Wochenschr       Date:  2010-03-10       Impact factor: 0.628

8.  Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) study.

Authors:  Giuseppe Patti; Massimo Chello; Dario Candura; Vincenzo Pasceri; Andrea D'Ambrosio; Elvio Covino; Germano Di Sciascio
Journal:  Circulation       Date:  2006-09-25       Impact factor: 29.690

Review 9.  Primary and secondary prevention of atrial fibrillation with statins and polyunsaturated fatty acids: review of evidence and clinical relevance.

Authors:  Irene Savelieva; Antonios Kourliouros; John Camm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2009-11-25       Impact factor: 3.000

10.  Angiotensin II receptor blockade reduces tachycardia-induced atrial adhesion molecule expression.

Authors:  Andreas Goette; Alicja Bukowska; Uwe Lendeckel; Michaela Erxleben; Matthias Hammwöhner; Denis Strugala; Jan Pfeiffenberger; Friedrich-Wilhelm Röhl; Christof Huth; Matthias P A Ebert; Helmut U Klein; Christoph Röcken
Journal:  Circulation       Date:  2008-01-28       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.